What is IGF-1 LR3?
IGF-1 LR3 is a modified insulin-like growth factor 1 analog. The Long R3 name refers to an extended N-terminus and an arginine substitution that are intended to reduce binding to IGF-binding proteins and prolong IGF-style signaling in research systems. [1][2][3]
That design makes the molecule biologically interesting, but it also separates it from prescription growth-hormone products and from normal circulating IGF-1 physiology. The key issue is whether this specific analog has route-matched human outcome and safety evidence. [1][2][3]
Product labels often collapse IGF-1, IGF-1 LR3, and research-grade IGF analogs into one category. Those products need separation because potency, binding-protein behavior, exposure, and anti-doping status can differ. [1][2][3]
What IGF-1 LR3 is investigated for
IGF-1 LR3 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Extended IGF-axis signaling
Injectable
Extended IGF-axis signaling
Injectable
Muscle growth and recovery support
Injectable
Muscle growth and recovery support
Injectable
Evidence snapshot
Overall confidence
IGF-1 LR3 has plausible IGF-axis activity, but controlled human outcome and safety data for this analog are thin. Muscle and recovery evidence remains separate from prescription growth-hormone or native IGF-1 evidence. [1][2][3][6]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
No direct controlled human outcome evidence establishes IGF-1 LR3 for muscle growth, recovery, or body composition. Human relevance is inferred from adjacent IGF-axis literature rather than product-specific results. [1][2][3][6]
Animal / preclinical
Laboratory and animal evidence supports IGF-axis activity and binding-protein differences. Translation to practical injectable outcomes remains uncertain. [1][2][3][6]
Mechanism support
The analog is designed for persistent IGF-1 receptor activity with reduced binding-protein constraint. That mechanism can affect protein synthesis, glucose handling, and cell-survival pathways, which explains both interest and caution. [1][2][3][6]
Forms & administration
IGF-1 LR3 appears as an injectable research-market peptide rather than an approved IGF-1 medicine. It is separate from prescription IGF-1 products because route, sterility, and growth-factor exposure are different. [9][1][2]
Dosing & protocols
The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.
Typical Range
Common injectable protocols usually use 20-50 mcg per dose. This range belongs to non-approved IGF-1 LR3 use, not prescription IGF-1 replacement. [9][1][2]
Frequency
Daily or training-day injectable schedules are the common calendar pattern. [9][1][2]
Timing Considerations
Morning or post-workout timing is the common anchor; meal timing is less central than consistency and training context. [9][1][2]
Cycle Length
Common injectable blocks run 4-6 weeks before reassessing body composition, recovery, glucose, edema, and adverse-effect notes. [9][1][2]
What to expect
First 1-2 weeks
Injectable/systemic IGF-axis exposure may show up as fuller training pumps, appetite shifts, body-weight water movement, and glucose-pattern changes. [1][2][3][6][9]
Weeks 4-6
Injectable/systemic recovery, training load, waist, body weight, and lean-mass appearance may settle into a clearer pattern. [1][2][3][6][9]
After stopping
Pump, fullness, and recovery signals may soften after injectable IGF-1 LR3 exposure ends, while training and nutrition determine whether body-composition changes hold. [1][2][3][6][9]
Safety profile
IGF-1 LR3 safety centers on systemic IGF-axis exposure: glucose symptoms, fluid shifts, growth-factor biology, injectable quality, and sport status matter more than ordinary injection comfort. [11]
Common side effects
Cautions
What we don't know
Human dose-response, immunogenicity, long-term metabolic effects, and product interchangeability remain poorly characterized for IGF-1 LR3. [11]
Who IGF-1 LR3 is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Insulin / glucose-lowering drugs
Insulin, sulfonylureas, or other glucose-lowering drugs can intensify or mask glucose symptoms during IGF-axis exposure; this is a GH/insulin-axis caution. [11]
- GH-axis products
Somatropin, GHRPs, or GH secretagogues can stack IGF-axis exposure, edema, and glucose effects; this is a theoretical pathway caution. [11]
- Anabolic hormones
Testosterone, anabolic agents, or strong bulking stacks can compound edema and growth-signal tracking; this is a theoretical pathway caution. [11]
Regulatory status
United States
In the U.S. as of 2026-06-21, IGF-1 LR3 has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket. [9][10][13][14]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved IGF-1 LR3 is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [9][10][13][14] | Not Listed IGF-1 LR3 is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval. [9][10][13][14] |
Injectable
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [16][17][18][19]
Sports & competition
WADA S2 applies to IGF-1 and related growth-factor activity; tested athletes should not treat injectable IGF-1 LR3 as athlete-cleared without a valid TUE or anti-doping review. [11][9][10][13][14]
How it works
IGF-1 LR3 is an IGF-1 analog designed for longer, less binding-protein-constrained IGF-1 receptor signaling than native IGF-1. That receptor pathway can push protein synthesis, glucose handling, cell survival, and tissue-growth signals, which explains the bodybuilding interest and the endocrine risk. [1][2][3][6]
The route caveat is central because the page is about injectable systemic exposure, not a food supplement or approved replacement product. Persistent IGF-axis signaling can overlap with glucose control, organ-growth, cancer-biology, and anti-doping concerns, so product identity and dose matter more than the shorthand name. [1][2][3][6]
Research gaps & open questions
What the current literature has not yet settled about IGF-1 LR3:
A key evidence gap is controlled human body-composition trials for the specific LR3 analog. [1][2][3][6]
A key evidence gap is route-specific pharmacokinetics and glucose-safety data. [1][2][3][6]
A key evidence gap is product identity and impurity testing across research-market materials. [1][2][3][6]
Common questions
Is IGF-1 LR3 FDA-approved?
Is IGF-1 LR3 the same as IGF-1?
Myths & misconceptions
Myth
IGF-1 LR3 is just another growth-hormone peptide.
Myth
Longer IGF-style signaling makes it better.
History & discovery
Long R3 IGF-1 entered the literature as a modified IGF-axis research tool, not as a finished medicine. The modification made it useful for studying IGF receptor signaling when ordinary binding proteins complicate interpretation. [1][2][3][6]
Animal and metabolic studies used IGF-1 LR3 to probe protein metabolism, glucose handling, and growth-factor signaling. That shaped later performance-market interest, but it did not create a controlled human muscle-growth program. [1][2][3][6]
Detection work on a black-market Long R3 IGF-I product shifted the story toward identity, purity, and anti-doping concerns. Market visibility therefore became a safety and enforcement issue, not clinical validation. [1][2][3][6]
11 studies
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
Am J Physiol Endocrinol Metab, 2025 Jan 1. animal.
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
J Dev Orig Health Dis, 2023 Jun. animal.
Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.
Domest Anim Endocrinol, 1999 May. animal.
IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.
J Endocrinol, 1997 Nov. animal.
Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.
J Endocrinol, 1996 Jul. animal.
Detection of His-tagged Long-R³-IGF-I in a black market product.
Growth Horm IGF Res, 2010 Oct. review.
The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I.
Am J Physiol, 1997 Jul. animal.
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.
J Alzheimers Dis, 2025 Jan. animal.
Drugs@FDA/openFDA query for IGF-1 LR3
U.S. Food and Drug Administration. database query.
Compounding and the FDA: Questions and Answers
U.S. Food and Drug Administration. official guidance.
The 2026 List of Prohibited Substances and Methods
World Anti-Doping Agency. regulatory.